Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Sarah Yuan
Observed name:
S Yuan
Institutions:
NewYork–Presbyterian Hospital,
University of South Florida,
Weill Cornell Medicine
Observed institutions:
NewYork–Presbyterian Hospital,
University of South Florida,
Columbia University Irving Medical Center,
Weill Cornell Medicine,
New York University
ORCID:
0009-0008-7361-1079
Observed ORCID:
0009-0008-7361-1079
OpenAlex ID:
A5016700027
Cholangiopathy After Severe COVID-19: Clinical Features and Prognostic Implications
2021
·
Saamia Faruqui
, Fidelis C. Okoli
, et al.
·
The American Journal of Gastroenterology
·
127
A Phase I Dose-Escalation/Expansion Study of Fractionated-Dose and Multiple-Cycle Anti–PSMA-Targeted α-Emitter 225Ac-J591 in Patients with Prostate Cancer
2026
·
Scott T. Tagawa
, Charlene Thomas
, et al.
·
Clinical Cancer Research
·
2
PDF
Effect of mammography screening frequency on false-positive biopsy rates and detection of local recurrence among breast cancer survivors.
2020
·
Julia E McGuinness
, Haley Manley
, et al.
·
Journal of Clinical Oncology
·
1
Abstract PD2-15: Effect of mammography screening frequency on false-positive biopsy rates and detection of local recurrence among breast cancer survivors
2018
·
S Yuan
, HJ Manley
, et al.
·
Cancer Research
·
1
Supplementary Figure S2 from A Phase I Dose-Escalation/Expansion Study of Fractionated-Dose and Multiple-Cycle Anti–PSMA-Targeted α-Emitter 225Ac-J591 in Patients with Prostate Cancer
2026
·
Scott T. Tagawa
, Charlene Thomas
, et al.
Supplementary Methods S1 from A Phase I Dose-Escalation/Expansion Study of Fractionated-Dose and Multiple-Cycle Anti–PSMA-Targeted α-Emitter 225Ac-J591 in Patients with Prostate Cancer
2026
·
Scott T. Tagawa
, Charlene Thomas
, et al.
Supplementary Table S7 from A Phase I Dose-Escalation/Expansion Study of Fractionated-Dose and Multiple-Cycle Anti–PSMA-Targeted α-Emitter 225Ac-J591 in Patients with Prostate Cancer
2026
·
Scott T. Tagawa
, Charlene Thomas
, et al.
Data from A Phase I Dose-Escalation/Expansion Study of Fractionated-Dose and Multiple-Cycle Anti–PSMA-Targeted α-Emitter 225Ac-J591 in Patients with Prostate Cancer
2026
·
Scott T. Tagawa
, Charlene Thomas
, et al.
Supplementary Figure S4 from A Phase I Dose-Escalation/Expansion Study of Fractionated-Dose and Multiple-Cycle Anti–PSMA-Targeted α-Emitter 225Ac-J591 in Patients with Prostate Cancer
2026
·
Scott T. Tagawa
, Charlene Thomas
, et al.
Supplementary Table S4 from A Phase I Dose-Escalation/Expansion Study of Fractionated-Dose and Multiple-Cycle Anti–PSMA-Targeted α-Emitter 225Ac-J591 in Patients with Prostate Cancer
2026
·
Scott T. Tagawa
, Charlene Thomas
, et al.
Supplementary Table S2 from A Phase I Dose-Escalation/Expansion Study of Fractionated-Dose and Multiple-Cycle Anti–PSMA-Targeted α-Emitter 225Ac-J591 in Patients with Prostate Cancer
2026
·
Scott T. Tagawa
, Charlene Thomas
, et al.
Supplementary Table S1 from A Phase I Dose-Escalation/Expansion Study of Fractionated-Dose and Multiple-Cycle Anti–PSMA-Targeted α-Emitter 225Ac-J591 in Patients with Prostate Cancer
2026
·
Scott T. Tagawa
, Charlene Thomas
, et al.
Supplementary Table S6 from A Phase I Dose-Escalation/Expansion Study of Fractionated-Dose and Multiple-Cycle Anti–PSMA-Targeted α-Emitter 225Ac-J591 in Patients with Prostate Cancer
2026
·
Scott T. Tagawa
, Charlene Thomas
, et al.
Supplementary Table S3 from A Phase I Dose-Escalation/Expansion Study of Fractionated-Dose and Multiple-Cycle Anti–PSMA-Targeted α-Emitter 225Ac-J591 in Patients with Prostate Cancer
2026
·
Scott T. Tagawa
, Charlene Thomas
, et al.
Supplementary Figure S1 from A Phase I Dose-Escalation/Expansion Study of Fractionated-Dose and Multiple-Cycle Anti–PSMA-Targeted α-Emitter 225Ac-J591 in Patients with Prostate Cancer
2026
·
Scott T. Tagawa
, Charlene Thomas
, et al.
Supplementary Table S5 from A Phase I Dose-Escalation/Expansion Study of Fractionated-Dose and Multiple-Cycle Anti–PSMA-Targeted α-Emitter 225Ac-J591 in Patients with Prostate Cancer
2026
·
Scott T. Tagawa
, Charlene Thomas
, et al.
Supplementary Figure S3 from A Phase I Dose-Escalation/Expansion Study of Fractionated-Dose and Multiple-Cycle Anti–PSMA-Targeted α-Emitter 225Ac-J591 in Patients with Prostate Cancer
2026
·
Scott T. Tagawa
, Charlene Thomas
, et al.
Laminin Expression and Function in the Central Nervous System
2026
·
Lingling Xu
, Sarah Yuan
, et al.
·
Proteoglycan Research
PDF
Abstract CT305: Fractionated (dose dense) and multiple dose PSMA-targeted alpha emitter 225Ac-J591 for advanced prostate cancer: Final primary and secondary outcomes
2026
·
Scott T. Tagawa
, Charlene Thomas
, et al.
·
Cancer Research
Changes in CTCAE v6: Effect on dose-escalation and dose-limiting toxicity with repeat analysis of recent clinical trials.
2026
·
Abdul Baseet Arham
, Escarleth Fernandez
, et al.
·
Journal of Clinical Oncology
PDF
Show more works
View as search
Works count:
20
Citation count:
131
H-index:
2
I10-index:
1
Year
Topic
Type